Coherus Files Four Petitions for Inter Partes Review of Abbvie’s Adalimumab-Related Patent


Today, Coherus Biosciences filed four petitions for inter partes review of Abbvie’s U.S. Patent 9,085,619 (IPR2017-00822IPR2017-00823, IPR2017-00826, and IPR2017-00827).  According to the petitions, the patent is drawn to formulations of adalimumab, commercially available under the brand-name Humira®.

Coherus already has three instituted IPR proceedings on patents related to adalimumab, IPR2016-00172, IPR2016-00188, and IPR2016-00189.  These proceedings are scheduled for oral hearing on February 16, 2017.

The newly filed petitions and other important IPR documents related to biologics are posted on our IPR tracker page.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.